Experimental compound T2 shows promise in limiting breast cancer progression in mouse model
Researchers found that thiosemicarbazone T2, an experimental compound, suppressed cancer progression in a mouse model of triple-negative breast cancer by blocking a key cellular signaling pathway. The study used an immunocompetent mouse model that mimics how human breast cancer progresses from non-invasive to invasive forms. The findings suggest T2 could warrant further investigation as a potential treatment for this aggressive form of breast cancer.
Scientists tested thiosemicarbazone T2, a compound previously shown to have anti-cancer effects, in a specialized mouse model of triple-negative breast cancer (TNBC). The compound reduced activity in the WNT/β-catenin signaling pathway, which plays a role in cancer cell invasion and spread. In the mouse model, T2 decreased the frequency of invasive lesions and altered expression of several proteins associated with cancer progression, while increasing levels of a metastasis-suppressing gene. The researchers observed that β-catenin protein localization differed between non-invasive and invasive cancer lesions, providing insight into the mechanism of action. These preclinical results suggest that targeting the WNT/β-catenin pathway through T2 may help prevent progression from early-stage to invasive breast cancer.
Limitations & open questions
The article does not discuss the current stage of drug development, timeline for potential human trials, or how T2 compares to existing triple-negative breast cancer treatments. Additionally, there is no mention of funding sources or potential conflicts of interest for the research team.
What different sources said
- bioRxivCenter
Thiosemicarbazone T2 suppresses WNT/β-catenin signaling and limits progression to invasive disease in a mouse intraductal model of triple-negative breast cancer
Related
Chinese Zhuque-2E Rocket Creates Spectacular Light Show Over Australia
A Chinese Zhuque-2E rocket launched from northwestern China created a dramatic light display visible across Queensland and northern New South Wales on Tuesday evening. The phenomenon occurred as the rocket released excess gases at high altitude where it remained illuminated by the sun despite darkness on the ground. The event highlights increasing commercial space activity and is expected to become more common as satellite launches accelerate.
NASA Announces Artemis III Crew for Earth Orbit Testing Mission
NASA has named four astronauts—Commander Randy Bresnik, Italian pilot Luca Parmitano, and US mission specialists Frank Rubio and Andre Douglas—to crew the Artemis III mission. The two-week mission will orbit Earth to test lunar landers and docking procedures rather than approach the moon, scheduled for launch in late 2027. This mission represents a critical step in NASA's plan to return astronauts to the lunar surface for the first time since the 1970s.
CSIR to Host RISE Conclave 2026 in Bengaluru, Featuring 100+ Start-ups and Innovation Showcase
The Council of Scientific and Industrial Research (CSIR) will organize the sixth RISE Conclave on June 13-14, 2026, in Bengaluru, bringing together researchers, industry representatives, start-ups, and policymakers to strengthen India's innovation ecosystem. The two-day event, themed "Innovation and Entrepreneurship Driven Growth for Viksit Bharat 2047," will feature over 100 start-ups, MSMEs, and technology exhibitors, with 12 ventures incubated at CSIR-CFTRI showcasing food technology products. The conclave aims to bridge the gap between laboratory research and market-ready solutions through collaboration and technology transfer opportunities.